Navigation Links
Studies find few risks to newborn offspring of parents who are childhood cancer survivors
Date:10/1/2009

SEATTLE Whether they can have children is one of the major concerns for adult survivors of childhood and adolescent cancer because fertility can be compromised by cancer treatment. For cancer survivors who can have children, two new studies led by researchers at Fred Hutchinson Cancer Research Center may help alleviate fears that their childhood disease will adversely impact their newborns.

The studies, presented as companion papers in the journal Archives of Pediatrics & Adolescent Medicine, observed few risks to babies born to parents who underwent cancer treatment in childhood or adolescence. The most significant finding was among women cancer survivors, who had a greater risk of giving birth to preterm and low birth weight infants compared to the general population. Among female cancer survivors, 15 percent of births were preterm versus 10 percent among women who never had cancer. However, babies born to female cancer survivors had no increased risk of birth defects or infant death, according to the paper that examined pregnancy outcomes.

In the companion paper, babies fathered by male childhood cancer survivors had a borderline risk of low birth weight but no increased risk of prematurity, being small for gestational age, or having birth defects when compared to controls.

"The take home message overall is positive. If you had cancer as a younger person and you are able to have children then most likely your children will be fine," said Eric Chow, M.D., Ph.D., corresponding author and research associate in the Hutchinson Center's Clinical Research and Public Health Sciences divisions. "Most of the other side effects that people have the most concern about birth defects and more serious maternal complications during pregnancy we didn't find those things."

Chow said pregnant women who had cancer in childhood should seek prenatal care early in their pregnancies and make sure their physicians and obstetricians know about their cancer history. Close monitoring may help prevent early births and underweight newborns.

A possible explanation for the increased rates of preterm delivery and underweight newborns found among female cancer survivors is that some cancer treatments may affect the growth of and blood flow to the uterus during pregnancy, said Chow, who is a pediatric oncologist. Previous studies have shown that radiation therapy to the uterus can increase the chances of subsequent preterm labor and low birth weight.

For the two papers, Chow and the principal investigator Beth Mueller, Ph.D., a cancer and reproductive health epidemiologist in the Hutchinson Center's Public Health Sciences Division, used data from cancer registries operated by the National Institutes of Health in four U.S. regions Seattle, Detroit, Salt Lake City and Atlanta. They identified boys and girls who were diagnosed with cancer before the age of 20 between 1973 and 2000. Linked birth records from the four regions identified the first live births to these survivors after diagnosis. A total of 1,898 offspring of female cancer survivors were identified and their outcomes were compared to 14,278 controls selected from birth records. The study identified 470 offspring of male cancer survivors and compared them to 4,150 controls.


'/>"/>

Contact: Dean Forbes
dforbes@fhcrc.org
206-667-2896
Fred Hutchinson Cancer Research Center
Source:Eurekalert

Related medicine news :

1. Penn studies point to strategies for reducing painful breast cancer drug side effects
2. Studies Evaluate Thyroid Treatment During Pregnancy
3. Studies Find PSA Screening Unreliable
4. Fructose Boosts Blood Pressure, Studies Find
5. ACP launches ethics case studies series on MedscapeCME
6. Kayentis, the Leading Provider of the Unique "Paper-Based e-Trial" Solution, has been Retained for Six New Clinical Studies in the US Market
7. MedWaves, Inc. Sponsors Investigational Studies to Evaluate Its Patented Microwave Thermal Coagulation-Ablation System for Treatment of Tumors in Liver and Lung
8. Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 - ESMO 34 Congress
9. One Dose of Swine Flu Vaccine Offers Protection: Studies
10. NIBIB scientists increase imaging efficiency in cell structure studies
11. FDA Study Indicates Most Industry Postmarketing Studies Meet Timelines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... , ... January 21, 2017 , ... Caronlab Australia, an ... the January ECRM Trade Show in Hilton Head, SC, where it benefited from outstanding ... the quality of its beauty and wellness products. At this trade show, the company ...
(Date:1/21/2017)... ... January 21, 2017 , ... Seamild, the largest manufacturer of oats ... of its owner and founder. As Oat is recognized globally as one of the ... personally as he believes it is a move to sow the seed of good ...
(Date:1/21/2017)... ... January 21, 2017 , ... Northern ... has recently joined their multi-specialty medical group. The dermatology practice provides general ... , “We’re excited to add this excellent dermatology practice to our group’s medical ...
(Date:1/21/2017)... Austin, Texas (PRWEB) , ... January 21, 2017 ... ... surgeries performed by Austin, Texas Periodontist Dr. Dan Holtzclaw in media for its ... features two surgeries performed by Dr. Holtzclaw in which he utilizes creos™ ...
(Date:1/20/2017)... ... ... Overseer at The House of Yahweh has posted a new publication this week pleading to ... time like no other and society needs to understand the only way to help make ... to sound like an old bible beater because religion has a bad rap these days ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... DUBLIN , Jan 20, 2017 ... "US Clinical Laboratory Testing Market By Type of Test (Tumor, ... Independent), & By Type of Diseases (Tuberculosis, Influenza, Cancer, HIV/AIDS ... ... an attractive destination for healthcare services, market segments, especially clinical ...
(Date:1/21/2017)... Calif. , Jan. 20, 2017 ARMO ... 1b clinical data on the Company,s lead investigational immuno-oncology ... Symposium, co-sponsored by the American Society of Clinical Oncology ... San Francisco, CA. "AM0010 ... activated CD8 + T cells in the blood ...
(Date:1/21/2017)... NEW YORK , Jan. 20, 2017  Faruqi & ... in KemPharm, Inc. ("KemPharm" or the "Company") (NASDAQ: ... against the Company and certain officers and directors and underwriters ... "IPO") to seek the role of lead plaintiff. ... District Court for Johnson County ...
Breaking Medicine Technology: